TY - JOUR
T1 - Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia
AU - Mostafa, Sam
AU - Rafizadeh, Reza
AU - Polasek, Thomas M.
AU - Bousman, Chad A.
AU - Rostami-Hodjegan, Amin
AU - Stowe, Robert
AU - Carrion, Prescilla
AU - Sheffield, Leslie J.
AU - Kirkpatrick, Carl M.J.
N1 - Funding Information:
The authors wish to acknowledge the contributions of the MAGERS study project team, study participants, clinicians at recruitment services, and staff at BC Psychosis Program (BCPP). The authors would also like to acknolwedge the staff at BC provincial toxicology centre for performing the clozapine assay and Sandrine Merette for assisting with questions on the assay. The MAGERS study received funding from the BC Schizophrenia Society and Foundation, UBC Development office (donations from Robert Baker and Elizabeth Carter), the Djavad Mowafaghian Centre for Brain Health, VGH, and UBC Hospital Foundation (donations from the James Family Foundation), UBC Neuropsychiatry ERIN Research Fund; and by in‐kind support from the UBC Institutes of Mental Health and Department of Psychiatry. Certara UK Limited (Simcyp Division) granted access to the Simcyp Simulators through a sponsored academic license.
Publisher Copyright:
© 2024 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
PY - 2024/3
Y1 - 2024/3
N2 - Model-informed precision dosing using virtual twins (MIPD-VTs) is an emerging strategy to predict target drug concentrations in clinical practice. Using a high virtualization MIPD-VT approach (Simcyp version 21), we predicted the steady-state clozapine concentration and clozapine dosage range to achieve a target concentration of 350 to 600 ng/mL in hospitalized patients with treatment-resistant schizophrenia (N = 11). We confirmed that high virtualization MIPD-VT can reasonably predict clozapine concentrations in individual patients with a coefficient of determination (R2) ranging between 0.29 and 0.60. Importantly, our approach predicted the final dosage range to achieve the desired target clozapine concentrations in 73% of patients. In two thirds of patients treated with fluvoxamine augmentation, steady-state clozapine concentrations were overpredicted two to four-fold. This work supports the application of a high virtualization MIPD-VT approach to inform the titration of clozapine doses in clinical practice. However, refinement is required to improve the prediction of pharmacokinetic drug–drug interactions, particularly with fluvoxamine augmentation.
AB - Model-informed precision dosing using virtual twins (MIPD-VTs) is an emerging strategy to predict target drug concentrations in clinical practice. Using a high virtualization MIPD-VT approach (Simcyp version 21), we predicted the steady-state clozapine concentration and clozapine dosage range to achieve a target concentration of 350 to 600 ng/mL in hospitalized patients with treatment-resistant schizophrenia (N = 11). We confirmed that high virtualization MIPD-VT can reasonably predict clozapine concentrations in individual patients with a coefficient of determination (R2) ranging between 0.29 and 0.60. Importantly, our approach predicted the final dosage range to achieve the desired target clozapine concentrations in 73% of patients. In two thirds of patients treated with fluvoxamine augmentation, steady-state clozapine concentrations were overpredicted two to four-fold. This work supports the application of a high virtualization MIPD-VT approach to inform the titration of clozapine doses in clinical practice. However, refinement is required to improve the prediction of pharmacokinetic drug–drug interactions, particularly with fluvoxamine augmentation.
UR - http://www.scopus.com/inward/record.url?scp=85182868341&partnerID=8YFLogxK
U2 - 10.1002/psp4.13093
DO - 10.1002/psp4.13093
M3 - Article
C2 - 38243630
AN - SCOPUS:85182868341
SN - 2163-8306
VL - 13
SP - 424
EP - 436
JO - CPT: Pharmacometrics & Systems Pharmacology
JF - CPT: Pharmacometrics & Systems Pharmacology
IS - 3
ER -